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498 The Journal of Thoracic and CardioObjective: The objective was to analyze the short- and long-term results of patients
with previous tricuspid valve repair who had valve dysfunction and required cardiac
reoperations.
Methods: Between 1976 and 2002, 74 patients with a mean age of 53.8 12.2 years
underwent valve reoperations for dysfunction of previous tricuspid valve repair.
Mitral and tricuspid lesions were diagnosed in 40 patients (54%), triple valve
disease (mitral, aortic, tricuspid) was diagnosed in 26 patients (35.1%), isolated
tricuspid disease was diagnosed in 6 patients (8.1%), and aortic and tricuspid lesions
were diagnosed in 2 patients (2.7%). Reoperations included tricuspid valve replace-
ment in 43 patients (58.1%) and a new tricuspid valve repair procedure in the
remaining 31 patients (41.9%).
Results: Hospital mortality (30-day or within first admission) was 35.1% (n  26).
In the multivariate analysis, risk factors for hospital mortality included body mass
index less than 20 kg/m2 and greater than 24 kg/m2, triple valve disease, use of
intra-aortic balloon counterpulsation, and presence of postoperative complications.
The follow-up was complete in 100% of patients, with a mean follow-up of 14.2
years (range 4 months to 26 years). The late mortality was 40.5% (n  30).
Predictors of late mortality were body mass index less than 20 kg/m2, cardiac
surgery before 1991, and development of dysfunction early after tricuspid valve
repair. At the follow-up closing date, 19 patients are alive (25.7%). The actuarial
survival was 11.8%  4.9% at 26 years.
Conclusions: Patients with failure of a tricuspid valve repair procedure requiring
reoperation have a poor prognosis with a high mortality rate both in-hospital and in
the long-term.
The current health care level in Spain is comparable to that of otheradvanced industrial countries, but the eradication of rheumatic fever is arecent occurrence. Therefore, left-sided valvular lesions and dysfunc-
tional tricuspid valves still have been diagnosed and treated with modern
technologies in a substantial number of patients.1,2 It is well known that
tricuspid disease associated with mitral or mitro-aortic valvular lesions may
result in poor early and late functional results.3,4 On the other hand, mortality
after prosthetic valve replacement is higher than after tricuspid valve annulo-
plasty.5,6 Little is known about the natural history of patients with polyvalvular
disease and tricuspid involvement undergoing tricuspid valve repair (annulo-
plasty and/or commissurotomy) who require reoperation for significant tricuspid
dysfunction. On the other hand, patients undergoing reoperation for tricuspid
valve dysfunction have scarcely been analyzed, and data of these cases are
mostly included in the general series of reoperations for valvular surgery.7-9 This
finding prompted us to review our experience with reoperations after tricuspid
valve repair and to determine those factors that influence early and late results.
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Between 1976 and 2002, 74 patients aged 53.77  12.19 years
(range 23-74 years) underwent reoperation for tricuspid valve
dysfunction of a previous tricuspid valve repair. There were 11
male patients and 63 female patients. Forty-six patients underwent
reoperation between 1976 and 1990, and the remaining 28 patients
underwent reoperation between 1991 and 2002. The reason to
divide the study period into 2 groups was related to the observation
of statistically significant differences in late mortality between
patients who underwent an operation before 1991 and after 1991.
The mean interval between reoperation and the first tricuspid valve
repair was 8.2  4.35 years. Forty-two patients (56.8%) were in
New York Heart Association (NYHA) functional class III, and 32
patients (43.2%) were in NYHA class IV. Main preoperative risk
factors included pulmonary hypertension in 62 patients (83.8%),
history of thromboembolic disease in 15 patients (20.3%), and
renal insufficiency in 4 patients (5.4%). On the other hand, phys-
ical signs of congestive heart failure (ascites, hepatomegaly, pe-
ripheral edemas, and/or distention of the jugular veins) were mod-
erate in 28 patients (37.8%) and severe in 12 patients (15.4%).
All patients had undergone the operation with extracorporeal
circulation, and tricuspid valve operation was performed after
surgical treatment of the mitral or aortic valve. Previous valve
operations included annuloplasty with a Duran flexible ring in 27
patients (36.5%), De Vega’s annuloplasty in 8 patients (10.8%),
segmental annuloplasty in 10 patients (13.5%), annuloplasty with
a Duran flexible ring and tricuspid commissurotomy in 24 patients
(34.5%), and other repair procedures in 5 patients (6.8%). Patients
with mitral lesions (n 74) underwent mitral valve repair (n 28,
37.8%) or prosthetic valve replacement (n  46, 62.2%). Patients
with aortic lesions (n  24) underwent aortic valve repair (n  6,
8.1%) or prosthetic valve replacement (n  8, 24.3%). The cause
was rheumatic heart disease in 66 patients (89.2%) and degener-
ative disease in 8 patients (10.8%). There were 47 patients (63.5%)
with organic tricuspid lesions and 27 patients (36.5%) with func-
tional tricuspid disease. Sixty-four patients had complete arrhyth-
mia caused by atrial fibrillation, and 10 patients were in sinus
rhythm.
All patients were investigated preoperatively by means of echo-
cardiography of different modes according to the year of the study,
in association with hemodynamic studies in 35 patients (47.3%),
particularly in those undergoing operation during the initial years
of the study. Tricuspid regurgitation was graded on a scale of 1
to 4. Hemodynamic data are given in Table 1.
After completion of echocardiographic and hemodynamic stud-
ies, mitral and tricuspid lesions were diagnosed in 40 patients
(54.1%), triple valve disease was diagnosed in 26 patients (35.1%),
isolated tricuspid disease was diagnosed in 6 patients (2.7%), and
aortic and tricuspid lesions were diagnosed in 2 patients (2.7%).
Tricuspid insufficiency was considered to be present in 60 patients
(81.1%), a double tricuspid lesion (stenosis and insufficiency) was
present in 9 patients (12.2%), and pure tricuspid stenosis was
present in the remaining 5 patients (6.8%). Grades of tricuspid
regurgitation were 3 in 16 patients and 4 in 44 patients.
Reoperation was indicated because of progression of valve disease
in 25 patients (33.8%), early failure of tricuspid valve repair in 11
patients (14.9%), prosthetic dysfunction in 24 patients (32.5),
The Journal of Thoraciprosthetic endocarditis in 4 patients (5.4%), and dehiscence of a
prosthesis in 10 patients (13.5%).
Reoperations were performed through a median sternotomy
with extracorporeal circulation. Forty-three patients (58.1%) un-
derwent prosthetic tricuspid valve replacement (mechanical pros-
thesis in 18 and bioprosthesis in 25). Repair of the tricuspid valve
was performed in 31 patients. Types of repairs were as follows:
flexible ring annuloplasty in 6 patients, a new De Vega’s or
segmental annuloplasty on a previous suture annuloplasty in 10
patients, resuture of the flexible ring in 7 patients, removal of the
flexible ring because of stenosis in 3 patients, Wooler-Reed annu-
loplasty at the posterior leaflet in 2 patients, closure of the antero-
posterior commissurotomy in 1 patient (this patient had a previous
commissurotomy), transverse section of a stenotic flexible ring in
1 patient, and suture of the anteroseptal commissure in 1 patient
(this patient had a previous commissurotomy).
Follow-up
The follow-up data for this study were procured in a 5-month
period (November 2003 to March 2004). The patients were fol-
lowed through visits in our outpatient clinic (n  29), direct
contact at home (n  10), or direct contact with their cardiologists
(n  6). When follow-up was not possible, information on vital
status (alive or death) was obtained through the Social Security
database (n  4). Follow-up was 100% complete, with a mean
follow-up of 14.2 years (range 4 months to 26 years).
Statistical Methods
The Patient Analysis and Tracking System database, version
06.02.03 (Dendrite Clinical System, Inc, Portland, Ore) was used.
Values are expressed as mean  SD. The Student t test was used
for the comparison of quantitative variables. Factors influencing
intrahospital mortality (ie, death before 30 days after surgery) were
analyzed using multiple logistic regression; its results are ex-
pressed as odds ratios. Survival curves were obtained by actuarial
method. Proportional hazards regression (Cox) was used to study
the influence of covariates on mortality and reoperation; we
present its results as hazard ratios. Multivariate analysis was per-
formed with the Stata Intercooled, release 6 (Stata Corporation,
College Station, Tex) computer program.
Results
Postoperative Complications
Severe postoperative complications developed in 48 pa-
TABLE 1. Results of preoperative hemodynamic studies
Parameter Mean  SD (range)
Pulmonary capillary pressure, mm Hg 23.75 6.46 (11-40)
Pulmonary artery systolic pressure,
mm Hg
56.40 18.41 (13-100)
Cardiac index, L · min · m2 2.34 0.66 (1.37-4.3)
Mitral valve gradient, mm Hg 14.72 7.35 (2-38)
Tricuspid valve gradient, mm Hg 6.79 3.93 (3-18)
Aortic valve gradient, mm Hg 30.92 16.05 (6-58)
Left ventricular ejection fraction, % 56.07 12.51 (22-88)tients (64.9%). Thirteen patients (17.6%) required an early
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nal dehiscence in 4, mediastinitis in 2, and epicardial pace-
maker implantation in 1. Infection of the sternotomy oc-
curred in 4 patients, and another patient presented with a
catheter-related sepsis. Six patients (8.1%) had an ischemic
stroke. Four of these patients were discharged without neu-
rologic deficit, and 2 patients had functional sequelae. Re-
spiratory complications developed in 10 patients (13.5%);
these patients required assisted ventilation for more than 5
days. Renal insufficiency was diagnosed in 20 patients
(27%), 6 of whom were treated with dialysis.
Hospital Mortality
The hospital mortality (30-day or within first admission)
was 33.8% (25 patients).
Causes of death were cardiac in 64% of cases, infection
in 8%, neurologic in 8%, renal failure in 8%, and bleeding
in 12%. Univariate analysis identified the grade of tricuspid
regurgitation, indication of reoperation, use of balloon
counterpulsation, and severe postoperative complications as
significant predictors of hospital mortality. The mean grade
of tricuspid regurgitation was 3.60  0.63 in deceased
patients and 3.36  0.48 in survivors (P  .002). The
mortality was 16.7% in patients in whom the reason of
reoperation was failure of a bioprosthesis and 42% for all
other indications (P  .033). The use of balloon counter-
pulsation had a significantly higher mortality (73.3% vs
23.7%, P  .005) as well as the presence of severe post-
TABLE 2. Predictors of mortality in the multivariate
analysis
P value
Hospital mortality* Odds ratio (95% CI)
BMI  24 kg/m2 4.91 (1.11-21.60) .035
BMI  20 kg/m2 5.22 (0.75-36.50) .096
Balloon counterpulsation 5.91 (1.32-26.47) .020
Severe postoperative
complications
10.24 (1.63-64.30) .013
Triple valve disease 2.90 (0.76-11.02) .118
Late mortality† Hazard ratio (95% CI)
Operation before 1991 9.24 (2.12-19.42) .0062
BMI  20 kg/m2 4.39 (1.19-23.45) .082
Indication of reoperation 6.89 (3.90-26.76) .034
Overall mortality‡ Hazard ratio (95% CI)
Operation before 1991 11.12 (4.56-30.98) .0012
BMI  20 kg/m2 4.89 (2.17-10.89) .078
Balloon counterpulsation 5.38 (2.34-19.89) .023
Severe postoperative
complications
12.12 (4.12-45.09) .093
Indication of reoperation 3.65 (0.68-8.46) .052
BMI, Body mass index; CI, confidence interval. *Pseudo R2  0.3352.
†Pseudo R2  0.3212. ‡Pseudo R2  0.3491.operative complications (45.8% vs 11.1%, P  .005).
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(BMI) less than 20 kg/m2 and greater than 24 kg/m2, triple
valve disease, use of intra-aortic balloon counterpulsation,
and severe postoperative complications were statistically
significant risk factors for hospital mortality (Table 2). The
area under the receiver operating characteristics curve was
0.8540.
Late Deaths
There were 30 late deaths among 49 perioperative survivors
(late mortality 40.5%). Causes of death were successive
reoperations in 5 patients, valve related in 9 patients, end-
stage heart failure in 11 patients, and unknown in 5 patients.
The actuarial survival was 11.8%  4.9% at 26 years
(Figure 1). In the univariate analysis, operation before 1991
and indication of reoperation were significant predictors of
late death. Mortality was 75% in patients who underwent
operation before 1991 and 35% in those who underwent
operation after 1991 (P  .008). Mortality was 100% in
operations performed for early failure of tricuspid valve
repair compared with 70.6% in operations performed for
failure of a bioprosthesis and 46.2% in operations per-
formed for progression of the disease (P  .049). There
were no significant differences between patients with and
without pulmonary hypertension, that is, preoperative val-
ues of pulmonary artery systolic pressure had no effect on
either early or late clinical outcome.
In the multivariate analysis, operation performed before
1991, BMI less than 20 kg/m2, and early failure of valve
repair as the indication for reoperation were significant risk
factors for late death (Table 2).
Overall Mortality
Overall mortality was 74.3%, with 19 survivors (25.7%).
Risk factors for death in patients undergoing tricuspid valve
reoperation included operation performed before 1991
(86.7% vs 55.2%, P  .005); use of an intra-aortic balloon
Figure 1. Actuarial survival curve after reoperations for failure of
previous tricuspid valve repair.counterpulsation (100% vs 67.8%, P  .011); early failure
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vs 70.3%, P  .047); and severe postoperative complica-
tions (85.4% vs 55.6%, P  .005). In the multivariate
analysis, risk factors for overall mortality were operation
performed before 1991, BMI less than 20 kg/m2, use of
balloon counterpulsation, and early failure of valve repair
(Table 2). Hospital mortality and late mortality were 41.8%
and 39.5%, respectively, for patients undergoing prosthetic
valve replacement. The corresponding figures for patients
undergoing a new tricuspid valve repair were 22.6% and
41.9%, respectively.
Reoperations
Of the 49 patients who survived the reoperation, 13 required
a third operation because of severe tricuspid insufficiency
associated with failure of tricuspid valve repair (n  1);
mitral and tricuspid dysfunction (n  1); mitral, aortic, and
tricuspid dysfunction (n  2); isolated mitral dysfunction
(n  4); isolated aortic dysfunction (n  1); and mitro-
aortic dysfunction (n  4). Indications of surgery included
dysfunction of mitral and/or aortic bioprosthesis in 7 cases,
prosthetic endocarditis in 1 case, and dehiscence of a pros-
thesis in 4 cases. In the 4 patients with a new tricuspid
disease, a bioprosthesis was inserted in all of them.
Three patients (23.1%) died at reoperation, and 10 pa-
tients (76.9%) were discharged from the hospital. Six of
these 10 patients underwent reoperation, 2 of whom died
(33.3%).
At the follow-up closing date, 15 of the 19 survivors
were in NYHA functional class I or II (78.9%), 3 survivors
were in class III (15.8%), and 1 survivor was in class IV
(5.3%). During the follow-up, 3 thromboembolic episodes
were recorded, 5 patients had hemorrhagic episodes related
to anticoagulation, and 1 patient had aortic prosthesis-
related endocarditis. The actuarial curve free from valve-
related complications was 9.6%  4.3% at 26 years (Figure 2).
Discussion
Rheumatic disease has been the most common cause of
tricuspid valve lesions in the past. In developed countries,
eradication of rheumatic disease was followed by a decrease
in the incidence of tricuspid valve lesions, with functional
regurgitation remaining as the most frequent cause. Clinical
and surgical management of tricuspid valve disease have
evolved from conservative approaches, that is, spontaneous
regression after correction of left-sided lesions, to a more
interventionist care. At present, it is well known that tricus-
pid regurgitation grades 3 and 4 that are not surgically
corrected or that reappear after operation are prognostic
factors of poor long-term outcome.10,11 On the other hand,
decisions concerning surgical treatment have also changed
from digital examination of the valve at operation to modern
preoperative diagnostic techniques of Doppler echocardiog-
The Journal of Thoraciraphy. In our country, the eradication of rheumatic fever
occurred later than in other industrialized countries, and for
this reason, tricuspid valve lesions of rheumatic origin have
been frequently seen in the recent past. Different studies
performed in the 1970s and 1980s have established the
clinical and hemodynamic criteria for surgical treatment of
left-sided valvular lesions.12,13 More recently, Doppler
echocardiography has been used to assess the severity of
right-sided valvular lesions and to establish the indication of
tricuspid vale repair based exclusively on echocardio-
graphic data.14
In our overall experience (1974-2002), 1080 patients
underwent 1178 surgical procedures on the tricuspid valve,
which included prosthetic valve replacement in 125 cases
(10.6%) and a valve repair technique in the remaining 1053
cases (89.4%). The majority of survivors of tricuspid valve
repair operations have an updated follow-up, some of them
included in previous studies,1,2 and are referred to our center
when a reoperation is necessary. An outstanding finding of
the present study is that tricuspid valve repair can be con-
sidered a curative procedure because in more than 25 years
of experience, repair operations of the tricuspid valve failed
in only 7% of the patients (n  74). Probably, no other
surgical valvular procedure shows this stability. This obser-
vation has also been reported by other authors.15 In agree-
ment with an extensive review recently published by Mc-
Carthy and associates,16 residual tricuspid regurgitation
grades 3 or 4 may even be acceptably tolerated by
patients; on the other hand, a reoperation of the tricuspid
valve is sometimes not indicated because of the high risk of
poor results. In the present series of 74 patients, failure of
tricuspid valve repair developed because of intrinsic dys-
function of the valve (n  6) and reappearance of left-sided
disease (n  68); these accounted for 0.6% and 6.4% of all
cases of tricuspid valve repair. Therefore, in defense of De
Vega’s and other suture annuloplasties17,18 it should be
Figure 2. Actuarial curve free from valve-related complications
after reoperations for failure of previous tricuspid valve repair.mentioned that an intrinsic failure of this technique is rare.
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experience with repair of tricuspid insufficiency, with a
mean freedom rate from tricuspid repair failure of 95% 
3%, 93%  3%, and 72%  8% at 5, 10, and 15 years,
respectively, after the De Vega semicircular annuloplasty.
It is well known that coexistence of a tricuspid valve
lesion with a mitral or mitro-aortic valvular disease has a
worse prognosis with an increased hospital mortality and,
particularly, a poor long-term outcome.2,20-22 In the study of
Mullany and associates,3 repair of tricuspid valve insuffi-
ciency in patients undergoing double (aortic and mitral)
valve replacement was associated with an actuarial survival
of 15% at 27 years, which is consistent with data reported
by others.4,20,21 In our experience, the actuarial survival
after tricuspid valve repair is 50.5% at 12 years.2 In agree-
ment with other studies,9,15 dysfunction after tricuspid valve
repair requiring reoperation was associated with a high
hospital mortality (33.8%) (combination of polyvalvular
heart disease and reoperation). In our experience, hospital
mortality after cardiac valve reoperations is greater than
early mortality after native valve surgery.23 A multivariate
Cox regression analysis for overall mortality revealed that
obesity (BMI  24 kg/m2), cachexia (BMI  20 kg/m2),
grade of tricuspid regurgitation, use of balloon counterpul-
sation, and severe postoperative complications were signif-
icantly associated with fatal outcome.
Late mortality was also high. Thirty patients died during
the 26-year follow-up period (40.5% of the initial series),
with a linear incidence of 2.1% patients per year and an
actuarial survival of 11.8%  4.9% at 26 years. These low
survival figures have also been reported by other authors,
such as a 15% survival at 27 years in the study of Mullany
and associates,3 a 25% survival at 15 years in the study of
McGrath and associates,4 or a 44% survival at 12 years in
the study of Kay and associates.22 In accordance with the
poor prognosis, the actuarial curve free from valve-related
complications was 9.6%  4.3% at 26 years, that is, in
approximately one third of a century there are no patients
with dysfunction of tricuspid valve repair requiring a reop-
eration who are free from valve-related problems. Of the
overall series of 74 patients, only 19 patients (25.7%) sur-
vived. End-stage heart failure was the most frequent
cause of late death. This observation together with other
findings indicates that an associated right ventricular
dysfunction and pulmonary hypertension are probably
the causes of tricuspid regurgitation and that this right-
sided disease is responsible for the poor clinical results
obtained. In addition, reoperations performed before
1991 showed an increased risk of late and overall mor-
tality compared with operations after 1991. This is an
expected finding related to general improvement of an-
esthetic and surgical techniques.
502 The Journal of Thoracic and Cardiovascular Surgery ● AuguIn conclusion, tricuspid vale repair is a long-term stable
procedure; however, valve dysfunction requiring reopera-
tion is associated with a high early and late mortality.
We thank Marta Pulido, MD, for editing the manuscript and for
editorial assistance.
References
1. Duran CM, Pomar JL, Colman T, Figueroa A, Revuelta JM, Ubago JL.
Is tricuspid valve repair necessary? J Thorac Cardiovasc Surg. 1980;
80:849-60.
2. Bernal JM, Gutiérrez-Morlote J, Llorca J, San Jose JM, Morales D,
Revuelta JM. Tricuspid valve repair: an old disease, a modern expe-
rience. Ann Thorac Surg. 2004;78:2069-75.
3. Mullany CJ, Gersh BJ, Orszulak TA, Schaff HV, Puga FJ, Ilstrup DM,
et al. Repair of tricuspid valve insufficiency in patients undergoing
double (aortic and mitral) valve replacement. Perioperative mortality
and long-term (1 to 20 years) follow-up in 109 patients. J Thorac
Cardiovasc Surg. 1987;94:740-8.
4. McGrath LB, Gonzalez-Lavin L, Bailey BM, Grunkemeier GL, Fer-
nandez J, Laub GW. Tricuspid valve operations in 530 patients.
Twenty-five-year assessment of early and late phase events. J Thorac
Cardiovasc Surg. 1990;99:124-33.
5. McGrath LB, Chen C, Bailey BM, Fernandez J, Laub GW, Adkins
MS. Early and late phase events following bioprosthetic tricuspid
valve replacement. J Card Surg. 1992;7:245-53.
6. Poveda JJ, Bernal JM, Matorras P, Hernando JP, Oliva MJ, Ochoteco
A, et al. Tricuspid valve replacement in rheumatic disease: preopera-
tive predictors of hospital mortality. J Heart Valve Dis. 1996;5:26-30.
7. Lytle BW, Cosgrove DM, Taylor PC, Gill CC, Goormastic M, Golding
LR, et al. Reoperations for valve surgery: perioperative mortality and
determinants of risk for 1,000 patients, 1958-1984. Ann Thorac Surg.
1986;42:632-43.
8. Jones JM, O’kane H, Gladstone DJ, Sarsam MA, Campalani G,
MacGowan SW, et al. Repeat heart valve surgery: risk factors for
operative mortality. J Thorac Cardiovasc Surg. 2001;122:913-8.
9. Hornick P, Harris PA, Taylor KM. Tricuspid valve replacement sub-
sequent to previous open heart surgery. J Heart Valve Dis. 1996;5:
20-5.
10. Kirali K, Omeoglu SN, Uzun K, Erentug V, Bozbuga N, Eren E, et al.
Evolution of repaired and non-repaired tricuspid regurgitation in rheu-
matic mitral valve surgery without severe pulmonary hypertension.
Asian Cardiovasc Thorac Ann. 2004;12:239-45.
11. Matsuyama K, Matsumoto M, Sugita T, Nishizawa J, Tokuda Y,
Matsuo T. Predictors of residual tricuspid regurgitation after mitral
valve surgery. Ann Thorac Surg. 2003;75:1826-8.
12. Ubago JL, Figueroa A, Ochoteco A, Colman T, Duran RM, Duran CG.
Análisis of the amount of tricuspid valve anular dilatation required to
produce functional tricuspid regurgitation. Am J Cardiol. 1983;52:
155-8.
13. Ubago JL, Figueroa A, Ochoteco A, Colman T, Duran RM, Duran CG.
Hemodynamic diagnosis of organic disease in the tricuspid valve. Rev
Esp Cardiol. 1980;33:5155-23.
14. Gonzalez-Vilchez F, Zarauza J, Vazquez de Prada JA, Martin Duran
R, Ruano J, Delgado C, et al. Assessment of tricuspid regurgitation by
Doppler color flow imaging: angiographic correlation. Int J Cardiol.
1994;44:275-83.
15. Donzeau-Gouge P, Villard A, Olivier M, Guibourg P, d’Allaines C,
Blondeau P, et al. Tricuspid reoperation in the surgery of rheumatic
valve diseases. Apropos of 24 cases. Arch Mal Coeur Vaiss. 1984;77:
255-61.
16. McCarthy PM, Bhudia SK, Rajeswaran J, Hoercher KJ, Lytle BW,
Cosgrove DM, et al. Tricuspid valve repair: durability and risk factors
for failure. J Thorac Cardiovasc Surg. 2004;127:674-85.
17. De Vega NG. Selective, adjustable and permanent annuloplasty. An
original technique for the treatment of tricuspid insufficiency. Rev Esp
Cardiol. 1972;25:555-6.18. Revuelta JM, Garcia Rinaldi R. Segmental tricuspid annuloplasty: a
new technique. J Thorac Cardiovasc Surg. 1989;97:799-801.
st 2005
Bernal et al Surgery for Acquired Cardiovascular Disease19. Carrier M, Pellerin M, Guertin MC, Bouchard D, Hebert Y, Perrault
LP, et al. Twenty-five years’ clinical experience with repair of tricus-
pid insufficiency. J Heart Valve Dis. 2004;13:952-6.
20. Czer LS, Maurer G, Bolger A, DeRobertis M, Kleinman J, Gray RJ,
et al. Tricuspid valve repair. Operative and follow-up evaluation by
Doppler color flow mapping. J Thorac Cardiovasc Surg. 1989;98:101-
11.
21. Carrier M, Pellerin M, Bouchard D, Perrault LP, Cartier R,The Journal of ThoraciHebert Y, et al. Long-term results with triple valve surgery. Ann
Thorac Surg. 2002;73:44-7.
22. Kay GL, Morita S, Mendez M, Zubiate P, Kay JH. Tricuspid regur-
gitation associated with mitral valve disease: repair and replacement.
Ann Thorac Surg. 1989;48:S93-5.
23. Echevarria JR, Bernal JM, Rabasa JM, Morales D, Revilla Y, Revuelta
JM. Reoperation for bioprosthetic valve dysfunction. A decade of
clinical experience. Eur J Cardiothorac Surg. 1991;5:523-7.c and Cardiovascular Surgery ● Volume 130, Number 2 503
A
CD
